netFormulary NHS
Demonstration Formulary
 Search
 Results

Looking for Bevacizumab found 25 matches

   


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (08.01.05)
link in drug section NICE TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (08.01.05)
link in drug section NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (08.01.03)
link in drug section NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (08.01.03)
link in drug section NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (08.01.05)
link in drug section NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (08.01.05)
link in drug section NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and pan (08.01.05)
link in drug section NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (08.01.05)
link in drug section NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (08.01.05)
link in drug section NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (08.01.05)
link in drug section NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (08.01.05)
link in drug section NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (08.01.03)
link in drug section NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (08.01.05)
link in drug section NICE TA285: Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (08.01.05)
link in drug section NICE TA666: Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (08.02.03)
link in drug section NICE TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (08.01.05)
link in drug section TA 118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (08.01.03)
link in drug section TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (08.01.05)
link in drug section TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (08.01.05)
link in drug section TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (08.01.03)


 
netFormulary